Advertisement

Current Cardiology Reports

, 21:128 | Cite as

A Cardio-Oncology Data Commons: Lessons from Pediatric Oncology

  • Anant MandawatEmail author
  • Logan Eberly
  • William Border
Cardio-Oncology (SA Francis and RB Morgan, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Cardio-Oncology

Abstract

Purpose of Review

To describe the role of big data in cardio-oncology.

Recent Findings

There is a trend towards developing cloud-based, integrated registries to improve data collection, access, and analysis.

Summary

Using a template from pediatric oncology, a cardio-oncology data commons is a novel opportunity to integrate data elements into a cloud-based platform. A cloud-based registry provides advantages of multi-institutional collaboration, rapid data access, a virtual visualization, and analytic tools to reduce infrastructure redundancy. The data commons would include integrated clinical data, blood samples, and genomic data to streamline discovery and analysis for researchers. A cardio-oncology data commons would be a large step forward in bringing cardio-oncology to the forefront of big data.

Keywords

Cardio-oncology Big data Data commons Pediatric oncology 

Notes

Compliance with Ethical Standards

Conflict of Interest

Anant Mandawat, Logan Eberly, and William Border declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Zamorano JL, Lancellotti P, Rodriguez Munoz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(36):2768–801.CrossRefGoogle Scholar
  2. 2.
    • Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017;35(8):893–911 Summary of the ASCO Clinical Guidelines for monitoring of cardiac dysfunction. CrossRefGoogle Scholar
  3. 3.
    Virani SA, Dent S, Brezden-Masley C, Clarke B, Davis MK, Jassal DS, et al. Canadian cardiovascular society guidelines for evaluation and management of cardiovascular complications of cancer therapy. Can J Cardiol. 2016;32(7):831–41.CrossRefGoogle Scholar
  4. 4.
    • Shapiro CL. Cancer Survivorship. N Engl J Med. 2018;379(25):2438–50 Summary of issues facing cancer survivors and illustration of the large growth in cancer survivors, particlarly those over age 65. CrossRefGoogle Scholar
  5. 5.
    Driver JA, Djousse L, Logroscino G, Gaziano JM, Kurth T. Incidence of cardiovascular disease and cancer in advanced age: prospective cohort study. BMJ. 2008;337:a2467.CrossRefGoogle Scholar
  6. 6.
    Lopez-Fernandez T, Martin Garcia A, Santaballa Beltran A, Montero Luis A, Garcia Sanz R, Mazon Ramos P, et al. Cardio-onco-hematology in clinical practice. Position paper and recommendations. Rev Esp Cardiol (Engl Ed). 2017;70(6):474–86.CrossRefGoogle Scholar
  7. 7.
    Mehta LS, Watson KE, Barac A, Beckie TM, Bittner V, Cruz-Flores S, et al. Cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the American Heart Association. Circulation. 2018;137(8):e30–66.CrossRefGoogle Scholar
  8. 8.
    • Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014;27(9):911–39 Summary of the ASE Guidelines for cardiac monitoring after cancer therapy. CrossRefGoogle Scholar
  9. 9.
    Mayer-Schonberger V, Ingelsson E. Big data and medicine: a big deal? J Intern Med. 2018;283(5):418–29.CrossRefGoogle Scholar
  10. 10.
    Patel JL, Goyal RK. Applications of artificial neural networks in medical science. Curr Clin Pharmacol. 2007;2(3):217–26.CrossRefGoogle Scholar
  11. 11.
    Dey D, Slomka PJ, Leeson P, Comaniciu D, Shrestha S, Sengupta PP, et al. Artificial intelligence in cardiovascular imaging: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;73(11):1317–35.CrossRefGoogle Scholar
  12. 12.
    Duarte CW, Lindner V, Francis SA, Schoormans D. Visualization of cancer and cardiovascular disease co-occurrence with network methods. JCO Clin Cancer Inform. 2017;(1):1–12.Google Scholar
  13. 13.
    Chen J, Long JB, Hurria A, Owusu C, Steingart RM, Gross CP. Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol. 2012;60(24):2504–12.CrossRefGoogle Scholar
  14. 14.
    Ezaz G, Long JB, Gross CP, Chen J. Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Heart Assoc. 2014;3(1):e000472.CrossRefGoogle Scholar
  15. 15.
    Tuzovic M, Yang EH, Sevag Packard RR, Ganz PA, Fonarow GC, Ziaeian B. National outcomes in hospitalized patients with cancer and comorbid heart failure. J Card Fail. 2019;25:516–21.CrossRefGoogle Scholar
  16. 16.
    Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018;71(16):1755–64.CrossRefGoogle Scholar
  17. 17.
    Ganatra S, Neilan TG. Immune checkpoint inhibitor-associated myocarditis. Oncologist. 2018;23(8):879–86.CrossRefGoogle Scholar
  18. 18.
    Volchenboum SL, Cox SM, Heath A, Resnick A, Cohn SL, Grossman R. Data commons to support pediatric cancer research. Am Soc Clin Oncol Educ Book. 2017;37:746–52.CrossRefGoogle Scholar
  19. 19.
    Armstrong GT, Chen Y, Yasui Y, Leisenring W, Gibson TM, Mertens AC, et al. Reduction in late mortality among 5-year survivors of childhood cancer. N Engl J Med. 2016;374(9):833–42.CrossRefGoogle Scholar
  20. 20.
    Armstrong GT, Oeffinger KC, Chen Y, Kawashima T, Yasui Y, Leisenring W, et al. Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J Clin Oncol. 2013;31(29):3673–80.CrossRefGoogle Scholar
  21. 21.
    Mulrooney DA, Yeazel MW, Kawashima T, Mertens AC, Mitby P, Stovall M, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the childhood cancer survivor study cohort. BMJ. 2009;339:b4606.CrossRefGoogle Scholar
  22. 22.
    Newman SZ, X, McLeod, C et. al. Access, visualize and analyze 5,000 whole-genomes from pediatric cancer patients on St. Jude Cloud [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14–18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 922.Google Scholar
  23. 23.
    St. Jude Cloud, Largest public repository of pediatric cancer genomics data, launches for researchers worldwide. The ASCO Post. April 20, 2018.Google Scholar
  24. 24.
    Childhood Cancer Data Initiative (CCDI) (originally published by the National Cancer Institute) National Cancer Institute [updated May 24 2019. Available from: https://www.cancer.gov/research/areas/childhood/childhood-cancer-data-initiative.
  25. 25.
    Ong M. Conversations with the cancer letter: sharpless: with $500 million, NCI can create data federation that would change research in childhood cancer. Cancer Lett. 2019:9–15.Google Scholar
  26. 26.
    Chung R, Ghosh AK, Banerjee A. Cardiotoxicity: precision medicine with imprecise definitions. Open Heart. 2018;5(2):e000774.CrossRefGoogle Scholar
  27. 27.
    Thavendiranathan P, Grant AD, Negishi T, Plana JC, Popovic ZB, Marwick TH. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. J Am Coll Cardiol. 2013;61(1):77–84.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Anant Mandawat
    • 1
    • 2
    • 3
    Email author
  • Logan Eberly
    • 1
    • 3
  • William Border
    • 4
    • 5
  1. 1.Division of Cardiology, Department of MedicineEmory University School of MedicineAtlantaUSA
  2. 2.Department of Hematology and Medical OncologyEmory University School of MedicineAtlantaUSA
  3. 3.Cardio-Oncology ProgramWinship Cancer Institute of Emory UniversityAtlantaUSA
  4. 4.Department of PediatricsEmory University School of MedicineAtlantaUSA
  5. 5.Sibley Heart Center, Children’s Healthcare of AtlantaAtlantaUSA

Personalised recommendations